Amgen (AMGN) Non-Current Deferred Tax Liability (2013 - 2026)

Amgen's Non-Current Deferred Tax Liability history runs 13 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• In Q1 2026, Non-Current Deferred Tax Liability fell 10.99% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $1.3 billion (down 10.99% YoY), while the FY2025 annual figure was $1.4 billion, down 15.47% from the prior year.
• Non-Current Deferred Tax Liability was $1.3 billion for Q1 2026 at Amgen, down from $1.4 billion in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $2.4 billion in Q4 2023 to a low of $11.0 million in Q4 2022.
• Historically, Non-Current Deferred Tax Liability has averaged $1.5 billion across 5 years, with a median of $1.5 billion in 2025.
• The sharpest annual moves came in 2023 and 2024: Non-Current Deferred Tax Liability jumped 21300.0% in 2023, then sank 31.35% in 2024.
• A 5-year view of Non-Current Deferred Tax Liability shows it stood at $11.0 million in 2022, then surged by 21300.0% to $2.4 billion in 2023, then tumbled by 31.35% to $1.6 billion in 2024, then dropped by 15.47% to $1.4 billion in 2025, then declined by 1.61% to $1.3 billion in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $1.3 billion (Q1 2026), $1.4 billion (Q4 2025), and $1.5 billion (Q3 2025), per Business Quant data.